Oxford Biomedica plc (OXBDF) Q4 2023 Earnings Call Transcript
…
£3,282
0,29%
Echtzeit-Aktienkurs Oxford Biomedica PLC
Bid:
Ask:
Nachrichten zur Oxford Biomedica PLC Aktie
Oxford Biomedica completes acquisition of ABL Europe
Oxford Biomedica completes acquisition of ABL Europe …
Global Gene Therapy Market Size to Worth USD 49.21 Billion by 2032 | CAGR of 20.46%
The Global Gene Therapy Market Size was valued at USD 7.65 Billion in 2022 and the Worldwide Gene Therapy Market…
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market…
Oxford BioMedica expands licence deal with Cabaletta Bio
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…
IN BRIEF: Oxford BioMedica launches lentiviral vector system
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…
Oxford Biomedica plc reports FY results
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…
Oxford BioMedica swings to full-year loss amid lower volumes
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…
Oxford Biomedica Posts FY Loss
LONDON (dpa-AFX) - Oxford Biomedica Plc. (OXB.L) reported that its loss attributable to owners of the company for the year…
Oxford BioMedica 2022 Results Delayed Due to Auditor Time Extension
Oxford BioMedica 2022 Results Delayed Due to Auditor Time Extension...…
Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023
Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023...…
IN BRIEF: Oxford BioMedica confirms start date of Mathias as new CEO
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…
Curate Biosciences Announces David Backer as Chief Executive Officer
Former Oxford Biomedica CCO to bring extensive cell and gene therapy commercialization expertise CARLSBAD, Calif., Dec. 16, 2022 /PRNewswire/ --…
IN BRIEF: Oxford Biomedica subsidiary signs deals with three US firms
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…
Oxford Biomedica Appoints Frank Mathias As CEO
LONDON (dpa-AFX) - Oxford Biomedica Plc (OXB.L), a British gene and cell therapy company, said on Tuesday that it has…
Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market…
IN BRIEF: Oxford BioMedica appoints Frank Mathias as new CEO
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…
Oxford Biomedica Appoints Frank Mathias as CEO
Oxford Biomedica Appoints Frank Mathias as CEO...…
Oxford BioMedica sells Windrush court facility for GBP60 million
Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...…
Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million
Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million...…
Oxford BioMedica Completes GBP60 Mln Sale, Leaseback of UK Facility
Oxford BioMedica Completes GBP60 Mln Sale, Leaseback of UK Facility...…